key: cord-0946365-r1oe4rwt
authors: Escalona‐Noguero, Carmen; López‐Valls, María; Sot, Begoña
title: CRISPR/Cas technology as a promising weapon to combat viral infections
date: 2021-02-11
journal: Bioessays
DOI: 10.1002/bies.202000315
sha: 58b3c2f301ac2ea1b38b5a969bb055b40600f474
doc_id: 946365
cord_uid: r1oe4rwt

The versatile clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system has emerged as a promising technology for therapy and molecular diagnosis. It is especially suited for overcoming viral infections outbreaks, since their effective control relies on an efficient treatment, but also on a fast diagnosis to prevent disease dissemination. The CRISPR toolbox offers DNA‐ and RNA‐targeting nucleases that constitute dual weapons against viruses. They allow both the manipulation of viral and host genomes for therapeutic purposes and the detection of viral nucleic acids in “Point of Care” sensor devices. Here, we thoroughly review recent advances in the use of the CRISPR/Cas system for the treatment and diagnosis of viral deleterious infections such as HIV or SARS‐CoV‐2, examining their strengths and limitations. We describe the main points to consider when designing CRISPR antiviral strategies and the scientific efforts to develop more sensitive CRISPR‐based viral detectors. Finally, we discuss future prospects to improve both applications. Also see the video abstract here: https://www.youtube.com/watch?v=C0z1dLpJWl4

The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas (CRISPR-associated proteins) system was described in 2005 [1] as an adaptive immune mechanism against viral and plasmid infections present in many bacteria. Depending on the number of components and their mechanism of action, CRISPR/Cas systems can be classified as Class 1 or Class 2. While Class 1 includes multi-subunitprotein complexes, Class 2 comprises single-effector proteins. The Class 2 CRISPR/Cas system consists of a Cas nuclease in complex with a guide RNA (crRNA) that can cleave a complementary target nucleic acid (DNA or RNA) ( Figure 1 , Table 1 ). [2] The specificity of the system can be then easily modulated by just modifying the crRNA sequence, enabling the controlled modification of DNA/RNA targets. [3] The potential of CRISPR Class 2 as a programmable gene-editing tool was first reported in 2013. [4] CRISPR system discovery and its development as a gene editing tool obtained the Nobel Prize in Chemistry in 2020.

Up to now, three Class 2 subtypes (II, V, and VI) have been used as biotechnological tools in numerous applications. RNA knock-down [8, 10] and also RNA editing by using catalytically inactive Cas13 (dCas13) ( Figure 1A ). [10] CRISPR/Cas system's versatility and specificity have broadened its range of applications, including molecular diagnosis and therapy. One of the most promising goals of this technology is the detection and treatment of viral infections. Viruses are the underlying cause for numerous acute and chronic disorders, and although some produce minor diseases, many others induce severe conditions, like the human immunodeficiency virus (HIV) and the recent SARS-CoV-2 pandemic.

An early diagnosis and effective treatment are critical to prevent their spread and reduce their prevalence. CRISPR technology is expected to play a prominent role in this context and its use as a sensor or as a therapeutic agent against viral infections is currently a growing field. In fact, the first CRISPR/Cas-based sensor for SARS-CoV-2 has been recently approved by the FDA.

Here, we review the most relevant existing and emerging applications of the CRISPR/Cas system for the treatment and diagnosis of viral infections.

The CRISPR/Cas system was discovered in bacteria as an in-built mechanism against viral infections, so it is only natural that this technology should be explored as an antiviral therapy. CRISPR/Casbased strategies have the potential to treat both acute and chronic

infections, but they are especially interesting for the latter. Many clinically relevant viral diseases often become chronic due to viral latency, a phase in which viral activity is minimal. Current treatments frequently lack efficacy in these cases. For instance, highly active antiretroviral therapy, the treatment of choice against HIV-induced acquired immunodeficiency syndrome, fails to target latent virus reservoirs. [11] The CRISPR/Cas system constitutes a promising tool for the definitive cure of these patients, who normally require life-long treatments. Although most research efforts have so far targeted HIV and hepatitis B virus, the CRISPR/Cas system has also demonstrated its therapeutic potential against herpesviruses, [12] human papilloma virus (HPV) [13] and dengue virus, [14] among others (Table 2) . Additionally, this technology has allowed to identify novel druggable antiviral targets [15] and contributed to the generation of disease models. [16, 17] The versatility of the CRISPR/Cas toolbox is one of its major [14] influenza A, lymphocyte choriomeningitis, and vesicular stomatitis viruses. [80] Interestingly, Cas13's applicability as a prophylactic for SARS-CoV-2 infections has been investigated too. [79] Besides the intrinsic versatility of the CRISPR/Cas system, these nucleases can be combined with antiviral drugs [58, 20] and other biomolecules, [82] greatly expanding therapeutic possibilities. This is especially limiting for infections lacking good animal models, such as hepatitis B. [22] In this section, we review the main aspects to consider when designing CRISPR-based antiviral strategies. The choice of adequate target genes and crRNAs is a key determinant not only for the effectiveness of antiviral therapies but also for their safety, since these two elements are closely related to off-target effects and the emergence of viral resistance. In addition, as mentioned above, the CRISPR/Cas system enables the generation of both knock-outs and knock-ins in specific loci and the transcriptional regulation of sequences of interest. This adaptability can be exploited to design strategies tailored to different therapeutic scenarios. Finally, we discuss different approaches for in vivo delivery, one of the main bottlenecks for CRISPR-based therapeutic applications.

The success of antiviral CRISPR therapy strongly relies on the choice of optimal target genes. Although research has mostly focused on viral nucleic acids, targeting host factors can also constitute a valuable approach ( Figure 2 ). [83] [58, 46, 54, 50] either alone or in combination with antiviral drugs. [58] Most of them are directed against the long terminal TA B L E 2 Overview of the main studies on the therapeutic applications of the CRISPR/Cas system against human viral infections Virus gRNA target Delivery method In vivo Ref.

Hepatitis B X, C, P Nucleofection/tail injection x [18] S, X Transfection [19] S, C, RT Lentiviral transduction [20] C, P, S, X Transfection/hydrodynamic injection x [21] C, P, S, X Transfection/hydrodynamic injection x [22] PreS, S, X, preC, C, EnhI Transfection [23] C, P, S, X Transfection/hydrodynamic injection x [24] S, P, X Transfection/hydrodynamic injection x [25] S, X, C Transfection [26] S, X, P Transfection/hydrodynamic injection x [27] C, P, S, X Lipid like nanoparticles x [28] repeated core region Transfection [29] S Adeno-associated viral transduction [30] C, P, S, X Transfection/hydrodynamic injection x [23] C, P, S, X Adeno-associated viral transduction x [31] RT, P, XCp High capacity adenoviral transduction [32] pre S1, pre S2/S Transfection x [33] S Transfection [34] Herpesvirus Viral miRNAs (EBV) Transfection [35] ICP0/4/7 (HSV) Transfection [36] UL54/57/70/105/86/84 (HCMV); UL8/29/52 (HSV); viral miRNAs (EBV) Lentiviral transduction [37] UL122/123 (HCMV) Lentiviral transduction [38] EBNA1, OriP, W repeats (EBV) Transfection [39] UL29, UL30, UL54/ICP27, RS1/ICP4 (HSV) Lentiviral transduction [40] LANA (Kaposi's sarcoma virus)

Adenoviral transduction [41] UL30, UL54 (HSV) Adeno-associated viral transduction x [12] Human immunodeficiency virus Viral elements LTR, gag, env, pol, vif, rev Transfection and lentiviral transduction [42] LTR, pol, rev Nucleofection [43] LTR, gag Adeno-associated viral transduction (tail injection)

x [44] LTR Transfection and lentiviral transduction [45] LTR Transfection and lentiviral transduction [46] LTR, gag, pol Lentiviral transduction [47] LTR, gag, env, pol, rev, tat Transfection and lentiviral transduction [48] gag, pol, env, rev Lentiviral transduction [49] LTR, gag, env, pol, tat, rev Lentiviral transduction [50] LTR, gag, pol Lentiviral transduction [51] LTR, gag, pol Lentiviral transduction [52] (Continues) LTR, gag, pol Adeno-associated viral transduction (IV injection)

x [53] LTR Adeno-associated viral transduction + synthetic surface peptide [54] TAR Lentiviral transduction [55] tat, rev Lentiviral transduction [56] LTR, gag, pol, vif, env, rev, tat Lentiviral transduction [57] LTR, gag Adeno-associated viral transduction x [58] Host factors CXCR4 Lentiviral transduction [59] APOBEC3G, APOBEC3B Transfection and lentiviral transduction [60] CCR5 Lentiviral and adenoviral transduction [61] CCR5/CXCR4 Lentiviral transduction [62] CXCR4 Lentiviral transduction [63] TRIM 5 Lentiviral transduction [64] CXCR4 Transfection [65] USP18 Nucleofection [66] mir146a Lentiviral transduction [67] CCR5/CXCR4 Lentiviral transduction [68] CCR5 Transfection [69] Latency reversal LTR Lentiviral transduction [70] LTR Transfection [71] LTR Transfection [72] LTR Transfection/nucleofection [73] Papillomavirus E7 Transfection [74] E6, E7 Transfection x [13] E6, E7 Transfection [75] E6, E7 Adeno-associated viral transduction x [76] E7 Self-assembled micelle x [77] E6 Adeno-associated viral transduction x [78] Cas13 Coronavirus RdRP, nucleocapsid NA (stable cell line expressing Cas13d) [79] Dengue virus Capsid, PrM, NS1, NS2a/b, NS3, NS4a/b, NS5, 3′UTR Transfection [14] Influenza A virus Viral mRNA (and complementary RNA) Transfection/electroporation [80] Lymphocyte choriomeningitis virus L and S segment Transfection/electroporation [80] Vesicular stomatitis virus N, P, L, G, M Transfection/electroporation [80] Cas12a HIV LTR, gag, env, pol, tat, rev, vpr, nef Lentiviral transduction [81] repeat (LTR) promoter regions. Virus clearance can be achieved through viral DNA/RNA disruption; however, "shock and kill" strategies may be used in quiescent infections to induce latency reversal. Host factors can be targeted either to boost host's immunity or to ablate those elements required for viral entry or replication. This technology has also enabled identification of novel druggable targets through the unravelling of virus-host interaction factors. The genetic engineering of non-model organisms that act as reservoirs has allowed the generation of novel disease models enhance host's antiviral response by inducing restriction factors that prevent viral replication [60] and inactivating elements that repress the immune response against HIV. [67] Host targeting approaches have been mostly limited to HIV infections, however, they may be useful against many other viruses. Different host factors, generally involved in viral entry or replication, have already been proposed as targets for CRISPR-based therapy against several infections. [83] Since genetic modifications are irreversible, host targets must be carefully selected to avoid deleterious side effects. In fact, the CRISPR/Cas system has contributed to identify potential host therapeutic targets, required for viral entry and replication but nonessential for the host. [84] Generally, targeting viral genomes is the preferred strategy as it constitutes a more straightforward and simple approach. Host-based therapies offer a valuable alternative and can contribute to overcome resistance issues: host genes are much less likely to experience mutations affecting crRNA recognition. However, targeting host factors requires a thorough evaluation of the chosen genes to ensure that they are dispensable for the host. Moreover, the irreversible modification of the host's genome may give rise to ethical concerns.

The design of crRNAs for the recognition of the chosen target gene(s) is also a key aspect to consider. Guide RNA's must simultaneously display high on-target activity and minimize off-target recognition. Although this is a general requirement for CRISPR/Cas designs, it becomes particularly important when applying this technology in vivo. Offtarget cleavage might have severe and unpredictable consequences and constitutes a major concern regarding the safety of CRISPR-based therapies. Antiviral CRISPR studies typically test numerous guides to find optimal sequences. In a recently published study on the use of CRISPR/Cas technology against SARS-CoV-2, Abbott et al. designed more than 3000 crRNAs in silico and evaluated the efficacy of 20 crRNAs per target gene. Eventually, they narrowed them down to a minimal pool of 6 crRNAs able to target 90% of all coronaviruses. [79] The use of individual crRNAs has generally been ineffective due to the emergence of viral escape mutants. Multiplex designs combining several crRNAs have consistently proven to be the best strategy to prevent viral resistance to CRISPR therapy. [52, 85, 86] This kind of designs typically involve combinations of at least three different crRNAs. [26, 32, 38, 53] Alternatively, the problem of viral resistance can be circumvented by targeting conserved viral genome regions where mutations are poorly tolerated. [79] crRNA design is often limited to predicted on-target and off-target scores and fails to consider the genetic robustness or fragility of the chosen site, which can crucially determine the efficacy of the editing strategy. In the case of Cas9, NHEJ in less conserved targets typically results in a three-nucleotide insertion. [48] When this short insertion occurs in a protein-coding region, the open reading frame and the coding capacity are likely to be preserved. further highlights the importance of thorough target site selection. [55] The multiplexing of highly specific crRNAs designed against conserved relevant viral genome sites constitutes the most promising strategy against viral escape mutants.

The vast majority of CRISPR-based antiviral approaches opt for the both therapeutically and prophylactically. [14, 79] In addition, CRISPRmediated knock-out generation has proven useful for the study of virus-host interactions and the identification of new therapeutic targets. These approaches use Cas9 in combination with multiplexed pools of crRNAs comprising the entire human genome to detect host factors involved in viral replication. [15] The highly versatile CRISPR/Cas system can also be applied to transcriptional regulation. Engineered catalytically inactivated dead Cas9

(dCas9) can be coupled with regulating factors to activate or repress transcription. [7] Several anti-HIV CRISPR studies have used dCas9mediated transcriptional activation with different goals. For example, the coupling of dCas9 with a synergistic activation mediator (SAM)

has proven useful to induce the expression of restriction factors that block HIV infection. [60] This kind of transcriptional regulation has also been exploited in the context of latency reversal, an alternative anti-HIV approach consisting in the reactivation of latent virus reservoirs to induce recognition and clearance by the immune system. Ji et al., for instance, used the dCas9-SunTag-VP64 system to reactivate latent HIV transcription in latently infected T-cell lines. [73] DNA DSBs repair through the homology directed pathway in presence of a donor template may also be exploited for the generation of knock-ins and precise gene editing. Unarguably, this strategy is infrequent among antiviral CRISPR approaches. Nonetheless, it has shown relative effectiveness in certain scenarios. Dufour et al., for example, used Cas9 to introduce two amino acid substitutions in the type I interferon-inducible human restriction factor TRIM5α to prevent HIV infection of human cells. [64] Interestingly, although they were able to edit and isolate several clones, none of them had all the alleles corrected, which illustrates the challenges faced by this kind of approaches.

The knock-out of viral genes is, by far, the most common strategy for antiviral CRISPR/Cas applications. This approach is generally more direct, efficient, and easier to design. CRISPR-mediated transcriptional regulation may also become a key instrument in the development of antiviral therapies as it is a versatile tool that can be adapted to different targets and therapeutic needs. Knock-in generation via HDR, on the other hand, possibly constitutes an unnecessarily complicated alternative. Since the HDR pathway occurs much less frequently than NHEJ, this kind of strategies show very low efficiency. Knock-in generation through the CRISPR/Cas system, however, has contributed to the generation of novel animal models enabling a better understanding of viral infections, and therefore, the development of improved therapies. [16, 17] Delivery strategies with in vivo translatability The use of mRNA, on the other hand, is limited by its low stability.

Direct RNP delivery is thus the preferred strategy for therapeutic applications. [87] Nevertheless, to our knowledge, in vivo RNP delivery

has not yet been studied for antiviral applications. Second, the delivery method for CRISPR effectors must be safe and efficient. Electroporation, nucleofection, and Lipofectamine-based transfection yield good results in vitro, but they are unsuitable for therapeutic purposes, with the exception of ex vivo treatments. [69] Viral-based strategies have been extensively tested for CRISPR delivery (Table 2) . However, they are mainly limited to mRNA and DNA delivery and they are known to be immunogenic, which hinders their in vivo potential. Widely used adeno-associated virus vectors show less immunogenicity, but they have two major drawbacks. On the one hand, they display strong tropism for specific organs and tissues, being thus unsuited for the targeting of certain cell types such as lymphocytes. [88] On the other hand, their low loading capacity is highly limiting considering the large size of Cas nucleases. [89] Therefore, non-viral delivery systems able to evade the immune system are of great interest. Nanotechnology constitutes a promising tool for the non-viral delivery of Cas-RNPs as it has the potential to overcome the main drawbacks of viral vectors: safety concerns and low loading capacity. A number of nanomaterials have already been used as Cas-RNPs carriers in other fields [90, 91] and their in vivo applicability has been demonstrated. [92] The surface of these nanomaterials is highly tuneable and can be modified for the 

Nucleic acid detection has been extensively used for molecular diagnosis of viral infections, mainly by quantitative polymerase chain reaction (qPCR). This is a highly specific and sensitive method, but requires sample preparation, high-cost equipment and materials, and special- Cas9 and Cas12 need the presence of PAM sequences in the target for further recognition (Figure 1 ). [3, 5] The genotype differences must then be located close to PAM sequences. Some Cas13 orthologs, like

Leptotrichia wadei (Lwa) Cas13a, completely lack this kind of sequence requirements. [8] However, Cas13 recognition is highly dependent on targets' secondary structure. Target RNA secondary structure must be carefully studied to design successful crRNAs and several guides must be tested for optimal detection. Despite these limitations, many relevant CRISPR-based sensors have been developed to detect viral nucleic acids (Table 3) .

Cas9's target recognition and cleavage were combined with isothermal amplification to develop two detection methods: CRISPR-Cas9triggered nicking endonuclease-mediated strand displacement amplification (CRISDA) [96] and NASBA-CRISPR. [95] The CRISDA method uses a pair of engineered Cas9 nickases that produce single-stranded breaks (nicks) on the target dsDNA. The cleavage triggers the strand displacement isothermal amplification of the target. This isothermal DNA in vitro amplification method uses a DNA polymerase together with restriction enzymes and different probes.

The resulting amplicon is detected by fluorescence measurement, using a peptide nucleic acid (PNA) labeled with biotin and Cy5, which is complementary to the middle region of the amplicon. The complex is isolated by streptavidin-coated magnetic beads and the fluorescence is recorded. This method presents attomolar (aM) sensitivity and singlenucleotide specificity. [96] F I G U R E 4 Most relevant CRISPR-based biosensing platforms. (A) SHERLOCK system scheme with different readouts: a single fluorescent reporter, lateral flow that provides a colorimetric readout using a FAM-Biotin reporter, and multiplex detection that uses a combination of Cas effector proteins and different fluorescent reporters. (B) HUDSON in combination with SHERLOCK to bypass the nucleic acid isolation step. (C) DETECTR system scheme NASBA-CRISPR is a low-cost detection system for ZIKV and DENV, two deleterious ssRNA viruses present in developing countries. The system is assembled in a paper-based platform and combines isothermal RNA reverse amplification, the ability of Cas9 to cleave specific target DNA and toehold switch sensors. [95] 

The success of Cas12 and Cas13-based sensors lays on their multipleturnover trans-cleavage activity. It is specifically activated by target recognition and allows signal amplification by adding reporter oligonucleotides that are substrates for the trans-activity. The recognition of one target molecule activates then the cleavage of many reporter [95] CRISDA DNA SDA aM Fluorescent 2-3 h N/S [96] Cas12 DETECTR DNA RPA aM Fluorescent 2 h HPV [6] Cas-gold DNA RPA aM Colorimetric Fluorescent 2 h ASFV [97] CRISPRresponsive hydrogel DNA/RNA RPA/RT-RPA aM Colorimetric 1 h Ebola [98] Naked-eye detection platform DNA/RNA PCR/RPA aM Colorimetric 1 h ASFV, miRNAs [99] STOPCovid RNA RT-LAMP aM Fluorescent Colorimetric 1-2 h SARS-CoV-2 [100] AIOD-CRISPR DNA/RNA RPA aM Fluorescent 0.5-1 h SARS-CoV-2 [101] Poly (A)-AuNPs DNA RPA -Naked-eye -ASFV [ [107] oligonucleotides. Both Cas12 and Cas13-based sensors are experi- LwaCas13a, which has not sequence restriction recognition, allows the potential detection of any ssRNA target. Nevertheless, the secondary structure of the target RNA must be studied to design suitable crRNA guides.

The first developed Cas13 and Cas12 detectors, named Specific

High-Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK) [103] and DNA endonuclease-targeted CRISPR trans reporter (DETECTR) [6] are based on the specific cleavage of previously amplified viral nucleic acid. This recognition triggers the trans-cleavage of quenched ssRNA or ssDNA fluorescent reporters, respectively. The fluorophore is then released, resulting in an increase in fluorescence (Figure 4 ). Both sensors have been used for the detection of several viruses with aM sensitivity [103, [108] [109] [110] [111] (Table 3) , including SARS-CoV-2. [108, 111] In fact, in May 2020 the FDA authorized the use of SHERLOCK for COVID-19 detection, and it has recently been clinically validated. [112] SHERLOCK is a DNA and RNA detection platform based on the SARS-CoV-2. [106] SHERLOCK and DETECTR have also been coupled to lateral-flow readout systems, to develop fully portable PoC detectors. [104, 97] In Figure 4A ). The Cas-Gold system relies on the same readout, but using LbCas12a and ssDNA oligonucleotides. [97] Interestingly, Barnes et al. have recently developed a mobile phone application that enables the quantification of the viral load from the paper strip based on the band intensity. [110] Although Those samples can be directly added to RPA reactions. [105] Interestingly, two recent publications show that it is possible to unify the isothermal amplification and target detection steps in one-pot, preventing cross-contamination in sample manipulation. The first one, STOPCovid (SHERLOCK testing in one-pot), uses the thermostable Alicyclobacillus acidophilus (Aap) Cas12b. The system is able to combine viral particles lysis and RNA extraction with one buffer in a short time, followed by RNA concentration using magnetic beads. Then, sample amplification is performed straight from the lysate by RT-LAMP, and Cas12b detection is performed in one-pot at 60 • C. The use of thermostable nucleases like AapCas12b is then the key point of this kind of methods. Besides, LAMP primers and crRNAs must be care-fully designed. Lateral-flow or fluorescence can be used as readout, allowing to detect aM concentration of SARS-CoV-2 N gene, similar to qPCR. [100] The all-in-one dual CRISPR-Cas12a combines RPA isothermal amplification and Cas12a RNP target recognition in one-pot. It is performed at 37 • C, so the better studied LbaCas12a is applied. [101] This method uses two LbaCas12a-crRNA RNPs, which interact with two different sites within the amplicon, very close to the RPA primers recognition sites. The RPA amplification and the Cas12a-crRNAs cleavage occur in parallel, together with the trans-cleavage activity.

The system lacks PAM sequence restriction because Cas12a lacks PAM requirements if the target sequence is already unwound. [113] The amplification reaction unzips Cas12a RNP target sites, allowing its PAM-free interaction with the DNA. Furthermore, the use of two Cas12a RNPs per target increases the specificity. Coupled to a fluorescent read-out, this method has been used to detect few copies of SARS-Cov-2 N gene in clinical samples, presenting aM sensitivity. [113] Undoubtedly, the most needed development of CRISPR-based sensors is to extend their detection limit to avoid prior sample isothermal amplification, as this implies an extra-step that must be optimized for every target. Qin et al. [107] [114] The recent coupling of CRISPR-based viral sensors with nanotechnology has opened a novel field with great potential. Bao When the MBs are separated using a magnetic field, the Qdots are pulled down, resulting in a colorless solution. When LbCas12a RNP and its target are previously added to the biotin-labeled probes, the targetactivated RNP cleaves the biotin probe and the Qdot-probes cannot bind the MBs, so the solution remains colored after magnetic MB separation. [115] This is a highly portable system due to the naked-eye readout. Its low sensitivity could be improved by coupling it with prior sample amplification. Hu et al. discovered a fast and efficient AuNPs coating method using poly (A) linkers, based on which they developed a diagnosis system. It relies on the same kind of read-out than Bao et al. but using AuNPs instead of Qdots. This method was able to detect ASFV from serum samples, after RPA isothermal amplification, although the limit of detection is not provided. They also designed an RNA detection system using AuNPs coated with ssRNA-FAM oligonucleotides and LbuCas13a. Upon target recognition, the FAM is released and can be detected by fluorescence. This alternative method was used to detect bacteria strains, but not viruses. [102] 

The CRISPR/Cas system has an enormous potential as a novel therapy against viral infections. The use of Cas nucleases not only enables the direct disruption of viral DNA and RNA in a highly specific manner but also allows to act on relevant host genes. Remarkably, CRISPR- CRISPR-based viral detection systems are rapid, versatile, specific, able of self-signal amplification, and sensitive. They are also especially suited for multiplex detection. [106] Many of the platforms here reviewed do not require expensive machinery, reagents, or specialized staff, making them an ideal tool for PoC applications. The future of this technology relies on the design of more sensitive and portable sensors.

Some studies have already shown that direct nucleic acid detection, without previous sample amplification, is possible. Further research to enhance Cas trans-cleavage activity and improve crRNA design will help increase sensitivity. Moreover, the combination of the CRISPR system with nanotechnology and nanofluidics will further enhance both the sensitivity and portability of diagnostic devices.

In conclusion, CRISPR/Cas technology constitutes an important tool to combat viral infections. It has a great therapeutic potential and could be applied soon, once safety and delivery issues are sorted out. Moreover, its use for viral detection is an actual fact.

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements

An updated evolutionary classification of CRISPR-Cas systems

A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity

Multiplex genome engineering using CRISPR/Cas systems

Crystal structure of Cpf1 in complex with guide RNA and target DNA

CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity

CRISPR-based technologies for the manipulation of eukaryotic genomes

RNA targeting with CRISPR-Cas13

C2c2 is a single-component programmable RNAguided RNA-targeting CRISPR effector

RNA editing with CRISPR-Cas13

HAART in HIV/AIDS treatments: Future trends

Gene editing and elimination of latent herpes simplex virus in vivo

In vitro and in vivo synergistic therapeutic effect of cisplatin with human papillomavirus16 E6/E7 CRISPR/CAS9 on cervical cancer cell line

CRISPR-Cas13a cleavage of dengue virus NS3 gene efficiently inhibits viral replication

A CRISPR toolbox to study virus-host interactions

Genome engineering with CRISPR-Cas9 in the mosquito Aedes aegypti

CRISPR/Cas9-mediated genome engineering of the ferret

Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication

CRISPR/Cas9 nickasemediated disruption of hepatitis B virus open reading frame

Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease

Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication

Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

An effective molecular target site in hepatitis B virus S gene for Cas9 cleavage and mutational inactivation

Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus

CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse

A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo

Removal of integrated hepatitis B virus DNA using CRISPR-Cas9

SsAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells

Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus

One-vector system for multiplexed CRISPR/Cas9 against hepatitis B virus cccDNA utilizing highcapacity adenoviral vectors

CRISPR/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells

Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus

CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells

Inhibition of HSV-1 replication by gene editing strategy

CRISPR/Cas9-mediated genome editing of herpesviruses limits productive and latent infections

Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential viral gene

Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR/Cas9

Herpesviral lytic gene functions render the viral genome susceptible to novel editing by CRISPR/Cas9

Reduction of Kaposi's sarcoma-associated herpesvirus latency using CRISPR-Cas9 to edit the latency-associated nuclear antigen gene

Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells

The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA

Excision of HIV-1 DNA by gene editing: A proof-of-concept in vivo study

Negative feedback regulation of HIV-1 by gene editing strategy

Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing

Anti-HIV-1 potency of the CRISPR/Cas9 system insufficient to fully inhibit viral replication

CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape

CRISPR/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape

A Combinatorial CRISPR-Cas9 attack on HIV-1 DNA extinguishes all infectious provirus in infected T cell cultures

Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS

A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape

In vivo excision of HIV-1 provirus by saCas9 and multiplex single-guide RNAs in animal models

Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes

Insights into the mechanisms underlying the inactivation of HIV-1 proviruses by CRISPR/Cas

CRISPR/Cas9 system targeting regulatory genes of HIV-1 inhibits viral replication in infected T-cell cultures

Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection

Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice

Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection

Specific induction of endogenous viral restriction factors using CRISPR/Cas-derived transcriptional activators

Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirusdelivered CRISPR/Cas9

Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection

CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection

Editing of the human TRIM5 gene to introduce mutations with the potential to inhibit HIV-1

HIV-1 inhibition in cells with CXCR4 mutant genome created by CRISPR-Cas9 and piggyBac recombinant technologies

CRISPR/Cas9 knockout of USP18 enhances type I IFN responsiveness and restricts HIV-1 infection in macrophages

CRISPR/Cas9-mediated deletion of miR-146a enhances antiviral response in HIV-1 infected cells

Simultaneous knockout of CXCR4 and CCR5 genes in CD4+ T cells via CRISPR/Cas9 confers resistance to both X4-and R5-tropic human immunodeficiency virus type 1 infection

CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia

CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs

Targeted HIV-1 latency reversal using CRISPR/Cas9-derived transcriptional activator systems

CRISPR-mediated activation of latent HIV-1 expression

Specific reactivation of latent HIV-1 by dCas9-SunTag-VP64-mediated guide RNA targeting the HIV-1 promoter

Reprogrammed CRISPR-Cas9 targeting the conserved regions of HPV6/11 E7 genes inhibits proliferation and induces apoptosis in E7-transformed keratinocytes

Deletion of HPV18 E6 and E7 genes using dual sgRNA-directed CRISPR/Cas9 inhibits growth of cervical cancer cells

Targeting HPV16 DNA using CRISPR/Cas inhibits anal cancer growth in vivo

HPV oncogene manipulation using nonvirally delivered CRISPR/Cas9 or Natronobacterium gregoryi Argonaute

CRISPR/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6

Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza

Programmable inhibition and detection of RNA viruses using Cas13

Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a system with only a single crRNA

The gRNA-miRNA-gRNA ternary cassette combining CRISPR/Cas9 with RNAi approach strongly inhibits hepatitis B virus replication

CRISPR-Cas targeting of host genes as an antiviral strategy

A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors

CRISPR/Cas9, a powerful tool to target human herpesviruses

Immunogenicity of Cas9 protein

Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins

Towards HBV curative therapies

AAV immunogenicity: A matter of sensitivity

Endosomal escape and delivery of CRISPR/Cas9 genome editing machinery enabled by nanoscale zeolitic imidazolate framework

Graphene oxidemediated Cas9/sgRNA delivery for efficient genome editing

Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair

Smart nanoparticles as targeting platforms for HIV infections

Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection

Rapid, low-cost detection of Zika virus using programmable biomolecular components

A CRISPR-Cas9-triggered strand displacement amplification method for ultrasensitive DNA detection

Rapid detection of African swine fever virus using Cas12a-based portable paper diagnostics

Programmable CRISPR-responsive smart materials

Universal and naked-eye gene detection platform based on the clustered regularly interspaced short palindromic repeats/Cas12a/13a system

Detection of SARS-CoV-2 with SHERLOCK one-pot testing

Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay

Single-step, salt-aging-free, and thiol-free freezing construction of AuNP-based bioprobes for advancing CRISPR-based diagnostics

Nucleic acid detection with CRISPR-Cas13a/C2c2

Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a and Csm6

Field-deployable viral diagnostics using CRISPR-Cas13. Science

Massively multiplexed nucleic acid detection with Cas13

Rapid and fully microfluidic ebola virus detection with CRISPR-Cas13a

CRISPR -Cas12-based detection of SARS-CoV-2

CRISPR-Cas13a nanomachine based simple technology for avian influenza A (H7N9) virus on-site detection

Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time

Ultra-sensitive and highthroughput CRISPR-p owered COVID-19 diagnosis

Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA

Direct observation of DNA target searching and cleavage by CRISPR-Cas12a

Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy

Magnetic Bead-Quantum Dot (MB-Qdot) Clustered Regularly Interspaced Short Palindromic Repeat Assay for Simple Viral DNA Detection

CRISPR/Cas technology as a promising weapon to combat viral infections

The authors declare no conflict of interest.

https://orcid.org/0000-0001-8763-0651